Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Prevention
Vaccine prevented high-grade cervical precancers in phase III study
November 3rd, 2005
CSL Limited announced that Gardasil, an investigational vaccine developed by Merck & Co., Inc., based on technology licensed from CSL, prevented 100% of high-grade cervical precancers and non-invasive cervical cancers (CIN 2/3 and AIS) associated with human papillomavirus (HPV) types 16 and 18 which account for 70% of all cervical cancers. The company advised that the trial compared Gardasil to placebo in women who were not infected with HPV 16 and 18 at enrollment and who remained free of infection through the completion of the vaccination regimen. A secondary analysis of the trial data demonstrated that even trial women who may have become infected...
Source: Women's Health Weekly (2005-11-03)
|
